NYSE:JNJ - Johnson & Johnson Stock Price, News, & Analysis

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Johnson & Johnson declared a quarterly dividend on Wednesday, January 2nd. Investors of record on Tuesday, February 26th will be given a dividend of $0.90 per share on Tuesday, March 12th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Monday, February 25th. View Johnson & Johnson's Dividend History.

Johnson & Johnson announced that its board has initiated a stock buyback plan on Monday, December 17th 2018, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 1.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's management believes its shares are undervalued.

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Tuesday, April, 17th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $2.00 by $0.06. The company earned $20.01 billion during the quarter, compared to analysts' expectations of $19.50 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company's revenue was up 12.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.83 EPS. View Johnson & Johnson's Earnings History.

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Johnson & Johnson.

Johnson & Johnson will be holding an earnings conference call on Tuesday, January 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Johnson & Johnson issued an update on its FY18 earnings guidance on Monday, December, 17th. The company provided earnings per share guidance of $8.13-8.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.16. The company issued revenue guidance of $81.0-81.4 billion, compared to the consensus revenue estimate of $81.39 billion.Johnson & Johnson also updated its FY 2018 guidance to $8.13-8.18 EPS.

13 analysts have issued 12-month price objectives for Johnson & Johnson's stock. Their predictions range from $110.00 to $160.00. On average, they anticipate Johnson & Johnson's share price to reach $139.5455 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Johnson & Johnson.

Press coverage about JNJ stock has trended extremely positive on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Johnson & Johnson earned a news sentiment score of 4.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.

Johnson & Johnson saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 15,719,662 shares, a decline of 19.9% from the December 14th total of 19,633,883 shares. Based on an average trading volume of 15,979,892 shares, the short-interest ratio is presently 1.0 days. Currently, 0.6% of the shares of the stock are sold short. View Johnson & Johnson's Current Options Chain.

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG) and Allergan (AGN).

Johnson & Johnson's stock is owned by many different of institutional and retail investors. Top institutional shareholders include DNB Asset Management AS (0.06%), Hexavest Inc. (0.06%), Gateway Investment Advisers LLC (0.05%), Confluence Investment Management LLC (0.04%), Nisa Investment Advisors LLC (0.04%) and BTIM Corp. (0.03%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

JNJ stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Atalanta Sosnoff Capital LLC, Sit Investment Associates Inc., USS Investment Management Ltd, Highland Capital Management LLC, Hexavest Inc., Moreno Evelyn V and Capital Investment Advisors LLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.

JNJ stock was purchased by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, DNB Asset Management AS, Ferguson Wellman Capital Management Inc., Weather Gauge Advisory LLC, QCI Asset Management Inc. NY, Centre Asset Management LLC, Nisa Investment Advisors LLC and Nachman Norwood & Parrott Inc. View Insider Buying and Selling for Johnson & Johnson.

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JNJ stock can currently be purchased for approximately $130.69.

Johnson & Johnson has a market capitalization of $350.63 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

The official website for Johnson & Johnson is http://www.jnj.com.

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.